Colorectal cancer risk reduction following macrogol exposure: a cohort and nested case control study in the UK.

Animal studies have demonstrated macrogol laxatives may reduce colorectal cancer (CRC) risk. This study aimed to investigate the association between macrogol prescribing and CRC risk.A case-control study nested within a cohort of laxative users was conducted using data from the UK General Practice R...

Full description

Bibliographic Details
Main Authors: Rachel A Charlton, Julia M Snowball, Katherine Bloomfield, Corinne S de Vries
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3869778?pdf=render
id doaj-c7c7edd74bc7457697af40a32ee42996
record_format Article
spelling doaj-c7c7edd74bc7457697af40a32ee429962020-11-25T02:48:44ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01812e8320310.1371/journal.pone.0083203Colorectal cancer risk reduction following macrogol exposure: a cohort and nested case control study in the UK.Rachel A CharltonJulia M SnowballKatherine BloomfieldCorinne S de VriesAnimal studies have demonstrated macrogol laxatives may reduce colorectal cancer (CRC) risk. This study aimed to investigate the association between macrogol prescribing and CRC risk.A case-control study nested within a cohort of laxative users was conducted using data from the UK General Practice Research Database. Six controls per case were identified and to account for the lead time of CRC, additional control sets were selected on the index date backdated by 1 to 5 years. Exposure to macrogols and covariate status before each of the backdated index dates was established. Conditional logistic regression was used to calculate the risk of CRC following macrogol prescribing adjusted for potential confounders.4734 incident CRC cases were identified; 2722, 2195, 1789, 1481 and 1214 had received a laxative prescription before the index dates backdated by 1 to 5 years. A suggestion of a non-significant reduction in CRC risk associated with 'macrogol after other laxative' prescribing was observed when the index date was backdated by 1 and 2 years, ORadj = 0.87 (CI950.74-1.03) and ORadj = 0.80 (CI950.65-1.00) compared to non-macrogol laxative exposure. The odds ratios reduced further and were significant when backdated by 3, 4 and 5 years, ORadj = 0.68 (CI950.50-0.92), ORadj = 0.60 (CI950.40-0.90) and ORadj = 0.30 (CI950.14-0.64) respectively. This reduction in risk was not observed, however, for 'macrogol only' and 'macrogol before other laxative' exposure categories.In this study we observed a reduced CRC risk associated with macrogol prescribing after accounting for the lead time for CRC. Further studies are required to determine whether the association is causal and whether it can partly be explained by selective prescribing.http://europepmc.org/articles/PMC3869778?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Rachel A Charlton
Julia M Snowball
Katherine Bloomfield
Corinne S de Vries
spellingShingle Rachel A Charlton
Julia M Snowball
Katherine Bloomfield
Corinne S de Vries
Colorectal cancer risk reduction following macrogol exposure: a cohort and nested case control study in the UK.
PLoS ONE
author_facet Rachel A Charlton
Julia M Snowball
Katherine Bloomfield
Corinne S de Vries
author_sort Rachel A Charlton
title Colorectal cancer risk reduction following macrogol exposure: a cohort and nested case control study in the UK.
title_short Colorectal cancer risk reduction following macrogol exposure: a cohort and nested case control study in the UK.
title_full Colorectal cancer risk reduction following macrogol exposure: a cohort and nested case control study in the UK.
title_fullStr Colorectal cancer risk reduction following macrogol exposure: a cohort and nested case control study in the UK.
title_full_unstemmed Colorectal cancer risk reduction following macrogol exposure: a cohort and nested case control study in the UK.
title_sort colorectal cancer risk reduction following macrogol exposure: a cohort and nested case control study in the uk.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2013-01-01
description Animal studies have demonstrated macrogol laxatives may reduce colorectal cancer (CRC) risk. This study aimed to investigate the association between macrogol prescribing and CRC risk.A case-control study nested within a cohort of laxative users was conducted using data from the UK General Practice Research Database. Six controls per case were identified and to account for the lead time of CRC, additional control sets were selected on the index date backdated by 1 to 5 years. Exposure to macrogols and covariate status before each of the backdated index dates was established. Conditional logistic regression was used to calculate the risk of CRC following macrogol prescribing adjusted for potential confounders.4734 incident CRC cases were identified; 2722, 2195, 1789, 1481 and 1214 had received a laxative prescription before the index dates backdated by 1 to 5 years. A suggestion of a non-significant reduction in CRC risk associated with 'macrogol after other laxative' prescribing was observed when the index date was backdated by 1 and 2 years, ORadj = 0.87 (CI950.74-1.03) and ORadj = 0.80 (CI950.65-1.00) compared to non-macrogol laxative exposure. The odds ratios reduced further and were significant when backdated by 3, 4 and 5 years, ORadj = 0.68 (CI950.50-0.92), ORadj = 0.60 (CI950.40-0.90) and ORadj = 0.30 (CI950.14-0.64) respectively. This reduction in risk was not observed, however, for 'macrogol only' and 'macrogol before other laxative' exposure categories.In this study we observed a reduced CRC risk associated with macrogol prescribing after accounting for the lead time for CRC. Further studies are required to determine whether the association is causal and whether it can partly be explained by selective prescribing.
url http://europepmc.org/articles/PMC3869778?pdf=render
work_keys_str_mv AT rachelacharlton colorectalcancerriskreductionfollowingmacrogolexposureacohortandnestedcasecontrolstudyintheuk
AT juliamsnowball colorectalcancerriskreductionfollowingmacrogolexposureacohortandnestedcasecontrolstudyintheuk
AT katherinebloomfield colorectalcancerriskreductionfollowingmacrogolexposureacohortandnestedcasecontrolstudyintheuk
AT corinnesdevries colorectalcancerriskreductionfollowingmacrogolexposureacohortandnestedcasecontrolstudyintheuk
_version_ 1724746994318049280